Review discusses complexity of immune-suppressive mechanisms in tumor milieu of cancers

Cancers control immune systems and evade immune detection using mediators consisting of immune checkpoint molecules and cellular systems associated with immune suppression.

In this review, the complexity of immune-suppressive mechanisms in the tumor milieu of cancers, including oral malignancy is discussed in relation to immune check point inhibitors, regulatory T cells (Treg), myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs). In addition, the therapeutic approach of oral pre-cancerous disorders is mentioned. Some reports also advocate that the immunosuppressive efficacy of the oral squamous cell carcinoma (OSCC) milieu is developed in a stepwise manner depending on the stages of OSCCs. Namely, in the early stage, CAFs could be a unique effector; humoral factor(s) from OSCC cells force CAF to exert immune suppression via the direct cell contacts to effector T cells. Potentiated CAF could also affect other immune-suppressive mediators such as Treg, tumor-associated macrophages (TAMs) and MDSCs. In the advanced stage of OSCC, MDSCs could possibly be a major conductor of immune-suppression. However, how OSCCs differentially utilize the immune modulatory aspects involving CAFs, MDSCs and several other factors is not fully understood. Further elucidation of the regulatory pathways structured by tumor-host interactions could identify important therapeutic targets in OSCC development.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New nanoparticle platform delivers drug pairs to specific cancer types